Previous Close | 14.55 |
Open | 14.35 |
Bid | 7.00 x 3000 |
Ask | 17.77 x 1100 |
Day's Range | 13.00 - 14.46 |
52 Week Range | 7.34 - 37.71 |
Volume | |
Avg. Volume | 105,524 |
Market Cap | 66.131M |
Beta (5Y Monthly) | 0.60 |
PE Ratio (TTM) | 45.78 |
EPS (TTM) | 0.31 |
Earnings Date | Mar 02, 2022 - Mar 07, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 40.75 |
SANTA MONICA, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), announced today that to protect the health and safety of its shareholders, employees, and communities amidst a rise locally in COVID-19, Opiant's 2022 Annual Meeting of Shareholders will be held in a virtual-only meeting format via live audio webcast. The meeting will be held online only and will begin at 09:00 AM PDT on June 14, 2022, as previously scheduled. The matters to be voted on
By David Bautz, PhD NASDAQ:OPNT READ THE FULL OPNT RESEARCH REPORT Business Update On May 10, 2022, Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) provided additional details from the positive pharmacodynamic (PD) study of OPNT003, for which the company had announced results a couple of weeks ago. A copy of the company’s presentation on the results can be found here . This was a single center,
SANTA MONICA, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended March 31, 2022, and provided a corporate update. Recent highlights include: Finance Update Q1 revenues of $4.5 million; $2.2 million of revenue was attributable to the license agreement with Emergent BioSolutions, Inc. (“EBS”) for the